AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jul 10, 2015

IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe

SUNNYVALE, Calif., July 10, 2015 /PRNewswire/ -- Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA® (ibrutinib) as the first treatment option available in all 28 member states of the European Union (EU) for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Pharmacyclics LLC, an AbbVie company, received FDA approval for IMBRUVICA, which is also the first and only FDA-approved treatment for WM in the United States, in January 2015.1 The approval of IMBRUVICA to treat patients with WM triggers a $20 million milestone payment from Janssen.

Jul 02, 2015

AbbVie to Host Second-Quarter Earnings Conference Call

NORTH CHICAGO, Ill., July 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2015 financial results on Friday, July 24, 2015, before the market opens.

Jun 29, 2015

AbbVie Expands Medical Device Facility in Sligo, Ireland With €40 Million Investment

SLIGO, Ireland, June 29, 2015 – AbbVie, a global biopharmaceutical company, today announced it will further expand its medical device manufacturing facility in Ballytivnan, Sligo, Ireland, and over the next four years, create 50 new highly-skilled jobs focused on devices that deliver AbbVie’s medicines to patients around the world. The investment is supported by the Industrial Development Authority (IDA) of Ireland and was announced today at an event attended by the Minister for Jobs, Enterprise and Employment, Richard Bruton, TD.

Jun 24, 2015

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin (RBV). These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.

Jun 12, 2015

AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders

NORTH CHICAGO, Ill., June 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data from studies of DUOPA® (carbidopa and levodopa) enteral suspension in patients with advanced Parkinson's disease during the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego.

Jun 12, 2015

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill., June 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced updated results of a Phase 1b study that showed patients with relapsed/refractory chronic lymphocytic leukemia (CLL) taking venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab, had an overall response rate (ORR) of 84 percent (n=41/49).1 Additionally, six patients stopped venetoclax after achieving either a complete response (CR) or CR with incomplete marrow recovery (CRi). Three patients maintained a response after a median of 12 months (0-21). These data were detailed in an oral presentation at the 20th Congress of the European Hematology Association (EHA), June 11-15, in Vienna.

Jun 09, 2015

AbbVie Presents Phase 3 Data Demonstrating Efficacy and Safety of HUMIRA® (adalimumab) in Children and Adolescents with Severe Chronic Plaque Psoriasis at the 23rd World Congress of Dermatology

- Results show HUMIRA is safe and effective for the treatment of severe chronic plaque psoriasis in pediatric patients

Jun 08, 2015

AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress

NORTH CHICAGO, Ill., June 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data on its investigational hematological malignancy medicines at the 20th European Hematology Association Annual Congress (EHA), June 11-14, in Vienna. Notable data include an oral presentation of venetoclax, an investigational B-cell lymphoma-2 (BCL-2) selective inhibitor, in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (R/R CLL) patients.

Jun 08, 2015

AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally

NORTH CHICAGO, Ill., June 8, 2015 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today launched its second annual Week of Possibilities volunteer program, with 3,100 employees globally volunteering more than 14,000 service hours to transform schools and communities where AbbVie employees live and work.